Cytokine-induced killer cells interact with tumor lysate–pulsed dendritic cells via CCR5 signaling

Lee, Hong Kyung; Kim, Yong Guk; Kim, Ji Sung; Park, Eun Jae; Kim, Boyeong; Park, Ki Hwan; Kang, Jong Soon; Hong, Jin Tae; Kim, Youngsoo; Han, Sang‐Bae

doi:10.1016/j.canlet.2016.05.020

Cited by 21 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been demonstrated that CCR5 is required to guide naive CD8 + T cells to CCL3/CCL4-secreting DC-CD4 + T cell complexes [38], orchestrating communication between DCs, CD4 + and CD8 + T cells in the draining lymph nodes [19]. Moreover, CCR5-dependent migration of NK cells towards TLR2/4-agonist-matured DCs has previously been described [20] and cytokine-induced killer cells use CCR5 signaling in the contact-dependent information exchange with DCs [62]. Furthermore, neutralization of CCL4 in the supernatant of virally activated plasmacytoid DCs resulted in > 80% inhibition of NK cell chemotaxis [22].…”

Section: Discussionmentioning

confidence: 99%

Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells

et al. 2017

View full text Add to dashboard Cite

Success of dendritic cell (DC) therapy in treating malignancies is depending on the DC capacity to attract immune effector cells, considering their reciprocal crosstalk is partially regulated by cell-contact-dependent mechanisms. Although critical for therapeutic efficacy, immune cell recruitment is a largely overlooked aspect regarding optimization of DC vaccination. In this paper we have made a head-to-head comparison of interleukin (IL)-15-cultured DCs and conventional IL-4-cultured DCs with regard to their proficiency in the recruitment of (innate) immune effector cells. Here, we demonstrate that IL-4 DCs are suboptimal in attracting effector lymphocytes, while IL15 DCs provide a favorable chemokine milieu for recruiting CD8+ T cells, natural killer (NK) cells and gamma delta (γδ) T cells. Gene expression analysis revealed that IL-15 DCs exhibit a high expression of chemokines involved in antitumor immune effector cell attraction, while IL-4 DCs display a more immunoregulatory profile characterized by the expression of Th2 and regulatory T cell-attracting chemokines. This is confirmed by functional data indicating an enhanced recruitment of granzyme B+ effector lymphocytes by IL-15 DCs, as compared to IL-4 DCs, and subsequent superior killing of tumor cells by the migrated lymphocytes. Elevated CCL4 gene expression in IL-15 DCs and lowered CCR5 expression on both migrated γδ T cells and NK cells, led to validation of increased CCL4 secretion by IL15 DCs. Moreover, neutralization of CCR5 prior to migration resulted in an important inhibition of γδ T cell and NK cell recruitment by IL-15 DCs. These findings further underscore the strong immunotherapeutic potential of IL-15 DCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells

et al. 2017

View full text Add to dashboard Cite

show abstract

“…ЦИК -это гетерогенная популяция эффекторных Т-клеток CD3 + CD8 + , которые могут быть получены из периферической крови, а также из пуповинной крови и костного мозга [39]. ЦИК способны убивать опухолевые клетки, используя механизмы FasL и перфорины (гранзимы) [40]. ЦИК состоят из фракций CD56-позитивных и CD56негативных клеток [41], причем Т-лимфоциты CD56 + считаются главной эффекторной субпопуляцией ЦИК.…”

Section: антитела конъюгированные с полимерными гранулами Plgaunclassified

Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)

Солопова¹,

Misyurin²

2019

Клиническая онкогематология

View full text Add to dashboard Cite

Лечебные моноклональные антитела давно уже стали важным инструментом в руках врачей разных специальностей, прежде всего онкологов. Появление биспецифических антител открыло новые горизонты для лечения рака, стало возможным привлечение собственного иммунитета пациента к борьбе с опухолью. В данном обзоре рассматриваются все форматы и стратегии, использованные при разработке биспецифических антител, дошедших до стадии клинических исследований, а также доступные результаты этих клинических исследований.

show abstract

“…They can kill tumor cells mediated by FasL and perforin (17). According to the presence of cell surface molecule CD56, CIK cells are also divided into two main subsets: CD3 + CD56 + T cells and CD3 + CD56 − T cells (18).…”

Section: What Is Cik?mentioning

confidence: 99%

“…As we all know, delivering TAAs to DCs as vaccines have been reported to be an effective strategy for the treatment of various advanced malignancies. The combination of DCs vaccination with CIK cells is considered to be more prospected, and studies showed a significantly stronger antitumor activity and fewer side effects (17, 66–69). Jung et al showed that in an in vivo animal model, the CIK + DC vaccination therapy was more effective than CIK or DC vaccination alone therapy for the treatment of hepatocarcinoma tumor cells (70).…”

Section: Improved Cik Therapymentioning

confidence: 99%

Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy

et al. 2017

View full text Add to dashboard Cite

Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD3+CD56+ natural killer T cells, which can be easily expanded in vitro from peripheral blood mononuclear cells. CIK cells work as pharmacological tools for cancer immunotherapy as they exhibit MHC-unrestricted, safe, and effective antitumor activity. Much effort has been made to improve CIK cells cytotoxicity and treatments of CIK cells combined with other antitumor therapies are applied. This review summarizes some strategies, including the combination of CIK with additional cytokines, dendritic cells, check point inhibitors, antibodies, chemotherapeutic agents, nanomedicines, and engineering CIK cells with a chimeric antigen receptor. Furthermore, we briefly sum up the clinical trials on CIK cells and compare the effect of clinical CIK therapy with other immunotherapies. Finally, further research is needed to clarify the pharmacological mechanism of CIK and provide evidence to formulate uniform culturing criteria for CIK expansion.

show abstract

Cytokine-induced killer cells interact with tumor lysate–pulsed dendritic cells via CCR5 signaling

Cited by 21 publications

References 21 publications

Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells

Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells

Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)

Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy

Contact Info

Product

Resources

About